Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term tafamidis in transthyretin amyloidosis
2009-011535-12Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafamidis in transthyretin amyloidosis (ATTR) and familial amyloid polyneuropathy (FAP), sponsored by Pfizer. Primary endpoint: Safety endpoints. Started May 2009; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2009-011535-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011535-12.